MNG57
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.522
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.503
- INTERFERON_ALPHA_RESPONSE+0.461
- IL6_JAK_STAT3_SIGNALING+0.458
- OXIDATIVE_PHOSPHORYLATION+0.435
- MYC_TARGETS_V2+0.434
- INTERFERON_GAMMA_RESPONSE+0.428
- ADIPOGENESIS+0.393
- INFLAMMATORY_RESPONSE+0.373
- PI3K_AKT_MTOR_SIGNALING+0.367
Top 10 suppressed
- SPERMATOGENESIS-0.225
- KRAS_SIGNALING_DN-0.222
- ANGIOGENESIS-0.099
- BILE_ACID_METABOLISM-0.066
- PANCREAS_BETA_CELLS-0.059
- CHOLESTEROL_HOMEOSTASIS-0.046
- ESTROGEN_RESPONSE_EARLY-0.045
- PROTEIN_SECRETION-0.040
- UV_RESPONSE_DN+0.008
- HEME_METABOLISM+0.055
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FBF510B1-3629-4FB9-BF9C-5BE689827DAC | — | — | 0.897 |
| 2 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.887 |
| 3 | MNG415 | — | — | 0.879 |
| 4 | MNG505 | — | — | 0.878 |
| 5 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.872 |
| 6 | 0F797735-CCCA-4BEA-BB94-C524E7D0A875 | — | — | 0.871 |
| 7 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.871 |
| 8 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.870 |
| 9 | BS_M8WP5T16 | low-grade glioma | — | 0.869 |
| 10 | C8955D29-D8EE-4F68-AEAC-CE1B838B22BF | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.522 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.503 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.461 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.458 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.435 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.434 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.428 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.393 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.373 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.367 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.364 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.347 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.325 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.306 | Idelalisib | — uncovered |
| COMPLEMENT | 0.305 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.304 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.296 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.248 | Idelalisib | — uncovered |